Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.

Bue-Valleskey, Juliana; Klaff, Leslie; Cho, Jang Ik; Dellva, Mary Anne; Schloot, Nanette C; Tobian, Janet; Miura, Junnosuke; Dahl, Dominik

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.

Bue-Valleskey, Juliana; Klaff, Leslie; Cho, Jang Ik; Dellva, Mary Anne; Schloot, Nanette C; Tobian, Janet; Miura, Junnosuke; Dahl, Dominik.

Afiliação

Bue-Valleskey J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA. bue-valleskey_juliana_m@lilly.com.
Klaff L; Rainier Clinical Research Center, Renton, WA, USA.
Cho JI; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Dellva MA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Schloot NC; Lilly Deutschland GmbH, Bad Homburg, Germany.
Tobian J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Miura J; Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Dahl D; Gemeinschaftspraxis fur Innere Medizin und Diabetologie, Hamburg, Germany.

Diabetes Ther ; 12(2): 569-580, 2021 Feb.

Article em En | MEDLINE | ID: mdl-33458803

Palavras-chave

Lispro; Type 1 diabetes; Ultra rapid lispro

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Diabetes Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google